Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hypertriglyceridemic hyperapoB in type 2 diabetes.

Allan D Sniderman1, Benoit Lamarche, Jessica Tilley

  • 1Mike Rosenbloom Laboratory for Cardiovascular Research, McGill University Health Centre, McGill University, Montreal, Canada. allan.sniderman@muhc.mcgill.ca

Diabetes Care
|March 5, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rethinking Cardiovascular Prevention in the Era of AI.

European journal of preventive cardiology·2026
Same author

How ultra-processed foods modulate cardiometabolic risk: A 2 × 2 factorial randomized controlled trial protocol in healthy adults.

Contemporary clinical trials·2026
Same author

Cost-Effectiveness of ApoB, Non-HDL-C, and LDL-C Goals for Primary Prevention Lipid-Lowering Therapy.

JAMA·2026
Same author

Developing and validating machine learning algorithms to predict various indices of diet quality among a socio-economically disadvantaged group.

The British journal of nutrition·2026
Same author

What are Canadians eating? A call to action for national surveillance and monitoring of dietary intakes in Canada.

Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme·2026
Same author

Targeting Triglycerides in Cardiovascular Disease Prevention: Evidence, Mechanisms, and Emerging Therapies.

Current cardiology reports·2026

In type 2 diabetes, using apolipoprotein B (apoB) to define dyslipidemia reveals more patients with elevated LDL particle number than LDL cholesterol alone. This highlights a more accurate method for identifying high-risk patients for intensive therapy.

Area of Science:

  • Cardiovascular Medicine
  • Metabolic Disorders
  • Lipidology

Background:

  • Type 2 diabetes is often associated with dyslipidemia, but LDL characteristics receive less focus than VLDL or HDL.
  • Limited data exist on apolipoprotein B (apoB) levels and dyslipidemic phenotypes in type 2 diabetes patients.
  • Most studies focus on mean lipoprotein levels, neglecting the frequency of different dyslipidemic patterns.

Purpose of the Study:

  • To investigate the prevalence of various dyslipidemic phenotypes in patients with type 2 diabetes.
  • To compare the diagnostic utility of LDL cholesterol versus apoB in classifying dyslipidemia.
  • To characterize the lipid profile associated with hypertriglyceridemic hyperapoB.

Main Methods:

  • Standardized measurement of plasma lipids, apoB, and apoA1.

Related Experiment Videos

  • Determination of LDL particle size using PAGE.
  • Phenotyping based on triglycerides and LDL cholesterol, and alternatively, triglycerides and apoB.

    • Main Results:

    • Elevated triglycerides and reduced LDL particle size were common; total and LDL cholesterol were generally normal.
    • Using LDL cholesterol, only 23% of patients showed abnormal LDL; using apoB, 40% had elevated LDL particle number.
    • The triglyceride-apoB-based approach identified nearly one-third of patients with hypertriglyceridemic hyperapoB, a group with severe dyslipoproteinemia.

    Conclusions:

    • The dyslipidemic profile in type 2 diabetes is heterogeneous, with some patients having normal lipid levels and LDL particle characteristics.
    • Defining dyslipidemia by triglycerides and apoB identifies a larger proportion of patients with abnormal LDL particle number compared to using LDL cholesterol.
    • Hypertriglyceridemic hyperapoB, characterized by high triglycerides, elevated LDL particle number, small dense LDL, and low HDL, is prevalent and associated with accelerated atherosclerosis, warranting aggressive treatment.